CRBAF
CRBAF operates in various business sectors.
CRBAF (CRBAF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.082x
Based on the latest financial reports, CRBAF (CRBAF) has a cash flow conversion efficiency ratio of 0.082x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-558.92K) by net assets ($-6.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CRBAF - Cash Flow Conversion Efficiency Trend (2022–2023)
This chart illustrates how CRBAF's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CRBAF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CRBAF ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
-0.525x |
|
Asiri Hospital Holdings PLC
CM:ASIRN0000
|
N/A |
|
BXNS
PINK:BXNS
|
N/A |
|
SUNAC CHINA HLDGS (SCNR.SG)
STU:SCNR
|
N/A |
|
Telemedpl
WAR:TMP
|
N/A |
|
Uniroyal Global Engineered Products Inc
PINK:UNIR
|
-0.443x |
|
Cuentas Inc
PINK:CUEN
|
0.486x |
|
Hemas Holdings PLC
CM:HHLN0000
|
N/A |
Annual Cash Flow Conversion Efficiency for CRBAF (2022–2023)
The table below shows the annual cash flow conversion efficiency of CRBAF from 2022 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-5.69 Million | $-1.11 Million | 0.195x | +109.67% |
| 2022-12-31 | $1.27 Million | $-2.55 Million | -2.016x | -- |